

MarketVue®
Sickle Cell Disease

January 2022



MarketVue®: Sickle Cell Disease

UNDERSTAND THE SICKLE CELL DISEASE MARKET

MarketVue market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Methodology: Research is supported by 4 qualitative interviews with key opinion leaders (U.S. Hematologists), a quantitative survey with 24 U.S. physicians and secondary research.

Geographies covered: United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

TOPICS COVERED

EPIDEMIOLOGY: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

CURRENT TREATMENT: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

UNMET NEEDS: Identify opportunities to address treatment or disease management gaps

PIPELINE ANALYSIS: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

VALUE AND ACCESS: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



MarketVue®: Sickle Cell Disease

UNDERSTAND THE SICKLE CELL DISEASE MARKET

COMPANIES MENTIONED

- Emmaus Medical
- Global Blood Therapeutics
- Novartis
- Bluebird Bio
- Forma Therapeutics / Novo Nordisk
- Agios
- Imara
- Aruvant Sciences
- Sangamo Therapeutics
- Vertex Pharmaceuticals
- CRSPR Therapeutics
- Novartis
- Intellia Therapeutics
- Novo Nordisk
- Pfizer

DRUGS MENTIONED

- L-glutamine (Endari)
- Crizanlizumab (Adakveo)
- Voxelotor (Oxbryta)
- BB305
- Canakinumab (Ilaris)
- Inclacumab
- Etavopiat / FT-4202
- Mitapivat / AG-348 (Pyrukynd)
- Tovinotrine / IMR-687
- ARU-1801
- BIVV-003
- CTX001
- OTQ923
- EPI01
- GBT021601
- PF-07209326

MarketVue®: Sickle Cell Disease

Table of Contents

1. DISEASE OVERVIEW	5 - 6
A chronic and progressive inherited genetic disorder	5
Figure 1.1 – Hemoglobin switching	5
Figure 1.2 – Key features of SCD	6
Sickle RBC morphology and function precipitates complications	6
Figure 1.3 – Impact of abnormal red blood cells on disease pathophysiology	6
2. EPIDEMIOLOGY & PATIENT POPULATIONS	7 - 9
Disease definition	7
Figure 2.1 – G6 diagnosed prevalent cases of SCD by region	7
Table 2.1 – Diagnosed prevalent and drug-treated patients in the G6	7
Key SCD population dynamics	8
Distinct phenotypes demarcate two market-relevant subpopulations	9
Figure 2.2 – SCD population segmented by annual VOC frequency	9
Figure 2.3 – SCD population segmented by predominant phenotype	9
Table 2.2 – Hb levels in healthy and SCD adults	9
Figure 2.4 – SCD population segmented by Hb levels	9
3. CURRENT TREATMENT	10 - 21
Disease management and treatment goals	10
New market entrants offer much needed expansion of treatment options	11
Table 3.1 – There are six treatment options for SCD	11
Figure 3.1 – Hematologist rating of current therapy effectiveness in SCD	11
Adakveo and Oxbryta use is on the rise	12
Figure 3.2 – SCD current treatment patient share	12
Standard of care: Hydroxyurea, a chemotherapy repurposed for SCD	13
Figure 3.3 – Reasons for hydroxyurea use	13
Clinical phenotype is a critical driver of Adakveo and Oxbryta prescribing	14
Novartis' Adakveo has carved out its place for reducing VOCs	15
Adakveo addresses a top unmet need, but barriers to its use remain	16
Figure 3.4 – Physician-reported barriers to Adakveo use	16
Oxbryta is viewed favorable for its fast response, efficacy, and tolerability	17
Figure 3.5 – Oxbryta advantages observed in clinical practice	17
Figure 3.6 – Hematologist-reported barriers to Oxbryta use	17
GBT's Oxbryta is experiencing slow but steady uptake	18

MarketVue®: Sickle Cell Disease

Table of Contents

Treatment decision in SCD – Oxbryta and Adakveo add new options and new complexity	19
Figure 3.7 – Treatment algorithm for the chronic management of SCD	19
Key treatment dynamics that shape disease management and drug use	20
Table 3.2 – Must-know treatment dynamics for now and the future	20
The outlook for current treatment and disease management is bright	21
Figure 3.8 – Timeline of SCD market evolution	21
4. UNMET NEED	22 - 25
Overview	22
Figure 4.1 – Top unmet needs in SCD	22
Figure 4.2 – Physician-reported unmet needs to SCD	22
Important unmet needs in treating SCD remain	23
Figure 4.3 – Three Cs of unmet need in SCD in wake of Adakveo and Oxbryta availability	23
The patient’s perspective on unmet need	24
Table 4.1 – FDA Voice of the Patient: insights from different SCD patients	24
Figure 4.4 – In the words of SCD patients	24
Non-clinical barriers to care – Physician and patient perspectives	25
Figure 4.5 – Hematologists’ perspective – barriers to patient care	25
Figure 4.6 – The patient’s perspective – barriers to care	25
5. PIPELINE ANALYSIS	26 - 31
Drug development for SCD is very active	26
Figure 5.1 – Number of emerging therapies addressing unmet needs in SCD	26
Figure 5.2 – Percentage of hematologists who rated emerging target or approach as “promising”	26
Summary of clinical-stage emerging SCD therapies	27
Table 5.1 – Emerging SCD therapies, Phase 2 and Phase 3	27
Table 5.2 – Emerging SCD therapies, Phase 1 and Phase 1/2	28
Figure 5.3 – Hematologists’ estimate of percent of SCD patients who are candidates for gene therapy	29
Figure 5.4 – Hematologists’ most likely use of gene therapy	29
Figure 5.5 – Types of patients who are candidates for gene therapy	30
Figure 5.6 – How physicians’ impression of Bluebird Bio’s technology changed in the past year	31
Figure 5.7 – Bluebird Bio’s BB305 Gene Therapy – upside and downside	31

MarketVue®: Sickle Cell Disease

Table of Contents

6. VALUE & ACCESS	32 - 34
Overview	32
Table 6.1 – Current therapy pricing	32
Table 6.2 – Typical commercial payer coverage of Adakveo an Oxbryta	32
Key market access dynamics that will continue to shape treatment use	33
Figure 6.1 – SCD patients by insurance type	33
Figure 6.2 – Actionable market access takeaways and lessons learned from Adakveo and Oxbryta	34
Figure 6.3 – Percentage of payer lives covered for Oxbryta reimbursement	34
7. METHODOLOGY	35 - 36
Primary market research methodology	35
Epidemiology methodology	36
Disease definition	36
Prevalence estimates	36

Meet the REACH Team



DANIELLE DRAYTON, PhD., Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



MELISSA CURRAN is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



MICHAEL HUGHES, MSc, Ph.D., Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

Meet the REACH Team



TYLER JAKAB, MPH is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



BAYLEY KOOPMAN is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



BRIANA MULLINS is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.